Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 12, 2007, Pages 2135-2142

  Kornberg, Arno ^a   Küpper, Bernadett ^a   Tannapfel, Andrea ^b   Bärthel, Erik ^a   Thrum, Katharina ^a   Settmacher, Utz ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Fibrosis; Inflammation; Interferon; Liver transplantation; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; AZATHIOPRINE; CYCLOSPORIN A; DACLIZUMAB; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS;

ADULT; AGED; ALLOGRAFT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; INFLAMMATION; LEUKOPENIA; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; NEUROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

EID: 36348934985     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04516.x     Document Type: Article

References (32)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002 122 : 889 96.
2. Berenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000 32 : 852 8.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C-virus infected recipients. Liver Transpl. 2003 9 : 28 34.
4. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002 8 : 14 18.
5. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 1999 19 (Suppl. 1 57 65.
6. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon-alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122 : 1303 30.
7. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 31 : 1426 32.
8. Samuel D, Bizollon T, Feray C et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003 124 : 642 50.
9. Lavezzo B, Franchello A, Smedile A et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J. Hepatol. 2002 37 : 247 52.
10. De Vera ME, Smallwood GA, Rosado K et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001 5 : 678 86.
11. Tannapfel A, Kohlhaw K, Ebelt J et al. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens. Transplantation 1999 67 : 1079 83.
12. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995 22 : 696 9.
13. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 5.
14. Berenguer M, Prieto M, san Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002 36 : 202 10.
15. Gane E, Portmann B, Naoumov N et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996 334 : 821 7.
16. Sanchez-Fueyo A, Restrepo JC, Quinto L et al. Impact of recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002 73 : 56 63.
17. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 2000 32 : 673 84.
18. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002 51 : 248 52.
19. Poynard T, Bedossa P, Opolon N. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 349 : 825 32.
20. Niederau C, Lange S, Heinges T et al. Prognosis of chronic hepatitis C. Hepatology 1998 28 : 1687 95.
21. Prieto M, Berenguer M, Rayon J et al. High incidence of allograft cirrhosis in HCV genotype 1b following transplantation. Hepatology 1999 29 : 250 6.
22. Samuel D. I favor therapy for hepatitis C virus recurrence after transplantation. Liver Transpl. 2002 8 : 55 8.
23. Abdelmalek MF, Firpi R, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004 2 : 199 207.
24. Bizollon T, Pradat P, Mabrut J-Y et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am. J. Transplant. 2005 5 : 1909 13.
25. Alberti AB, Belli LS, Airoldi A et al. Combined therapy with interferon and low-dose ribavirin in post-transplantation recurrent hepatitis C: a pragmatic study. Liver Transpl. 2001 7 : 870 6.
26. Stravitz RT, Shiffmann ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 2004 10 : 850 8.
27. Narayanan Menon K, Poterucha J, El-Amin O et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 8 : 623 9.
28. Pelletier SJ, Lezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl. 2000 6 : 44 53.
29. Rodriguez-Luna H, Khatib A, Sharma P et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series. Transplantation 2004 2 : 190 4.
30. Wiesner R, Sorrell M, Villamil F and the International Liver Transplantation Society Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003 9 (Suppl. 3 1 29.
31. Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995 27 : 1222 3.
32. Dousser B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N. Engl. J. Med. 1994 330 : 1160 1.